Universal Protection Against Infectious Bursal Disease (IBD) Induced By The Vector Vaccine VAXXITEK® HVT+IBD

Lemiere S. & Rojo F. 


Clinical protection against all pathotypes of the serotype 1 infectious bursal disease virus is induced, from the classical viruses to the very virulent and the variants, by the HVT-IBD vector vaccine VAXXITEK HVT+IBD. Clinical protection means protection against clinical signs of the disease, mainly with the very virulent form, mortality, hemorrhage, stringent bursa atrophy, as well as protection against immunosuppression in the variant forms of the disease. Such clinical protection and therefore protection against the negative consequences of immunosuppression, poor vaccine take, occurrence of intercurrent diseases, and huge negative impact on production performances is uniquely obtained with a vector vaccine HVTIBD vaccination that allows early onset of immunity, either in ovo at transfer time around 18 days of embryonation, or at day old in the hatchery, in presence of IBD virus maternally-derived antibodies.